Medexus Pharmaceuticals Inc (MDP) AI Stock Analysis

• Market Cap: C$88.39M
• Dividend Yield: N/A
• Average Volume (3M): 39.16K
• Price to Earnings (P/E): 21.3
• Beta (1Y): 0.97
• Revenue Growth: -1.14%
• EPS Growth: N/A
• Country: CA
• Employees: 82
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.03
• Shares Outstanding: 32,258,354
• 10 Day Avg. Volume: 29,147
• 30 Day Avg. Volume: 39,162
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$6.67
• Price Target Upside: 144.32% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 69 Neutral
• Price Target: C$3.00 ▲(9.89% Upside)

Medexus Pharmaceuticals shows strong financial performance and promising corporate developments, particularly with GRAFAPEX. However, technical indicators suggest caution, and valuation metrics are moderate. The company's ability to manage liabilities and operational efficiency will be crucial for future performance.

Positive Factors

Market Demand

Canadian unit demand for Trecondyv grew 70% and the drug holds a significant market share in pediatric and adult alloHSCT markets in Canada.

Product Launch

Positive signs are seen in the launch of Grafapex.

Regulatory Approval

U.S. FDA approves Treosulfan, marking a significant benefit to patients.

Negative Factors

Product Profitability

Management has decided to no longer sell Gleolan in the U.S. as the product was not profitable.

Regulatory Challenges

Medexus faces a negative Health Canada setback for Terbinafine.

Revenue Decline

Total revenues decreased 4.6% year-over-year, a decline expected due mainly to generic pressure on Rupall.

Medexus Pharmaceuticals Inc Business Overview & Revenue Model

Company Description

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. It focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, and allergy. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, a prescription allergy medication. Its products portfolio also includes Treosulfan, a bifunctional alkylating agent for allogeneic hematopoietic stem cell transplantation; Trispan, a triamcinolone hexacetonide injectable suspension; and Gleolan, an optical imaging agent indicates for patients with glioma symptoms. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Bolton, Canada.

How the Company Makes Money

Medexus Pharmaceuticals Inc. generates revenue primarily through the sale of its pharmaceutical products. The company's revenue streams are derived from direct sales to healthcare providers, hospitals, and pharmacies in North America. Medexus's business model also includes strategic partnerships and licensing agreements that expand its product portfolio and market reach. These partnerships often involve collaborations with other pharmaceutical companies to co-promote or distribute products, thereby enhancing revenue potential. Additionally, Medexus may receive milestone and royalty payments from licensing arrangements, contributing to its overall earnings.

Medexus Pharmaceuticals Inc Financial Statement Overview

Summary

Medexus Pharmaceuticals has demonstrated strong revenue growth and improved profitability despite some operational efficiency issues. The company's strengthened equity position and reduced leverage are positives, though high total liabilities remain a concern.

Income Statement

Medexus Pharmaceuticals has shown strong revenue growth over the years, particularly from 2022 to 2024, with a slight dip in 2025. The Gross and Net Profit Margins have improved significantly, suggesting better cost management and increased profitability. However, fluctuations in EBIT margins highlight some operational efficiency issues.

Balance Sheet

The company has strengthened its equity position over the years, with a substantial increase in stockholders' equity from 2022 to 2025. The Debt-to-Equity ratio has decreased, indicating reduced leverage. However, high total liabilities still pose a risk to financial stability.

Cash Flow

Operating cash flow has improved significantly, turning positive after periods of negative cash flow. The Free Cash Flow Growth Rate is robust, supporting financial flexibility. However, fluctuations in investing and financing cash flows suggest ongoing capital adjustments.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	108.33M	113.05M	108.10M	76.70M	79.66M
Gross Profit	56.58M	59.51M	60.04M	37.93M	42.01M
EBITDA	16.81M	19.28M	16.14M	15.16M	-23.61M
Net Income	2.25M	-214.00K	1.22M	-2.88M	-28.26M
Balance Sheet
Total Assets	171.84M	155.73M	161.33M	139.22M	148.51M
Cash, Cash Equivalents and Short-Term Investments	23.97M	5.25M	13.07M	10.02M	18.70M
Total Debt	37.18M	49.90M	94.72M	54.86M	56.40M
Total Liabilities	119.69M	125.41M	187.70M	151.82M	130.50M
Stockholders Equity	52.14M	30.32M	22.45M	17.79M	18.02M
Cash Flow
Free Cash Flow	21.31M	18.45M	-1.81M	-8.89M	-5.72M
Operating Cash Flow	24.03M	18.71M	-1.44M	-1.18M	5.04M
Investing Cash Flow	-6.00M	-3.48M	-1.72M	-8.20M	-11.70M
Financing Cash Flow	796.00K	-23.05M	6.41M	663.00K	18.68M

Medexus Pharmaceuticals Inc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.73
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MDP, the sentiment is Negative. The current price of 2.73 is below the 20-day moving average (MA) of 2.81, below the 50-day MA of 2.95, and below the 200-day MA of 2.89, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 44.20 is Neutral, neither overbought nor oversold. The STOCH value of 38.08 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MDP.

Medexus Pharmaceuticals Inc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RX	75 Outperform	C$131.35M	16.73	22.17%	1.66%	16.55%	14.70%
MDP	69 Neutral	C$88.39M	21.26	5.27%	―	-1.14%	―
Sector *	51 Neutral	$7.37B	0.24	-62.86%	2.36%	15.01%	-2.64%
AQS	21 Underperform	C$663.17K	―	43.02%	―	129.21%	26.79%
WIB	―	C$1.96M	―		―	―	―
MPH	47 Neutral	C$11.58M	―	-8.79%	―	-0.29%	-53.83%
OGI	―	$184.17M	20.29	4.76%	―	―	―

Medexus Pharmaceuticals Inc Corporate Events

Medexus Pharmaceuticals Announces First Fiscal Quarter 2026 Conference Call

Medexus Pharmaceuticals has scheduled a conference call on August 13, 2025, to discuss its first fiscal quarter results for the period ending June 30, 2025. The company will also participate in upcoming industry conferences, reflecting its active engagement in commercialization activities and maintaining its market presence.

The most recent analyst rating on (TSE:MDP) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.

Medexus Pharmaceuticals’ GRAFAPEX™ Receives NTAP Approval for 2026

Medexus Pharmaceuticals announced that GRAFAPEX™ (treosulfan) for Injection has received approval for New Technology Add-On Payment (NTAP) from the US Centers for Medicare & Medicaid Services for the fiscal year 2026. This approval marks a significant reimbursement milestone, allowing eligible procedures involving GRAFAPEX™ to receive additional reimbursement, thereby enhancing its accessibility to Medicare beneficiaries. Since its US commercial launch, GRAFAPEX™ has seen positive uptake, with several commercial payers and healthcare institutions including it in their formularies, indicating promising commercial potential.

The most recent analyst rating on (TSE:MDP) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.

Medexus Pharmaceuticals Reports Strong FY 2025 Results and Successful GRAFAPEX Launch

Medexus Pharmaceuticals reported strong fiscal year 2025 results, highlighted by the successful U.S. launch of GRAFAPEX (treosulfan) following FDA approval. Despite a slight decrease in overall revenue, the company achieved record net income and Adjusted EBITDA, driven by financial discipline and strategic investments. The launch of GRAFAPEX has shown promising initial market uptake, with positive formulary inclusion from major payers and healthcare institutions, indicating significant future revenue potential. Medexus expects GRAFAPEX to contribute positively to cash flows by fiscal Q4 2026, enhancing its market position in the rare disease treatment segment.

The most recent analyst rating on (TSE:MDP) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.

Medexus Pharmaceuticals Announces Fiscal Year 2025 Financial Results Conference Call

Medexus Pharmaceuticals has announced a conference call scheduled for June 26, 2025, to discuss its financial results for the fourth fiscal quarter and fiscal year ending March 31, 2025. This announcement is significant for stakeholders as it provides insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor relations.

The most recent analyst rating on (TSE:MDP) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on Medexus Pharmaceuticals Inc stock, see the TSE:MDP Stock Forecast page.